AR and neoplasm: For these men, androgen deprivation therapy (ADT) is standard of care and while initially effective at reducing tumor burden, residual cancer cells adapt to low systemic androgen levels and therapy resistant metastatic castrate-resistant prostate cancer (mCRPC) develops, where tumorigenesis is driven by adaptive androgen receptor (AR) changes and intra-tumoral steroid biosynthesis (7).